Using the galectin-3 test to predict mortality in heart failure patients

• Verfasst von: Chen, Yueh-Sheng [VerfasserIn]
• Verfasst von: Gi, Weng-Tein [VerfasserIn]
• Verfasst von: Liao, Tin-Yun [VerfasserIn]
• Verfasst von: Lee, Meng-Tse Gabriel [VerfasserIn]
• Verfasst von: Lee, Si-Huei [VerfasserIn]
• Verfasst von: Hsu, Wan-Ting [VerfasserIn]
• Verfasst von: Chang, Shy-Shin [VerfasserIn]
• Verfasst von: Lee, Chien-Chang [VerfasserIn]
• Titel: Using the galectin-3 test to predict mortality in heart failure patients
• Titelzusatz: a systematic review and meta-analysis
• Verf.angabe: Yueh-Sheng Chen, Weng-Tein Gi, Tin-Yun Liao, Meng-Tse Gabriel Lee, Si-Huei Lee, Wan-Ting Hsu, Shy-Shin Chang and Chien-Chang Lee
• E-Jahr: 2016
• Jahr: 9 February 2016
• Umfang: 14 S.
• Fussnoten: Gesehen am 30.04.2020
• Titel Quelle: Enthalten in: Biomarkers in medicine
• Ort Quelle: London : Future Medicine, 2007
• Jahr Quelle: 2016
• Band/Heft Quelle: 10(2016), 3, Seite 329-342
• ISSN Quelle: 1752-0371
• DOI: doi:10.2217/bmm.15.121
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1696934265

Abstract

Aim: Galectin-3 (Gal-3) is a new biomarker for assessing prognosis of heart failure (HF) patients. This systemic review and meta-analysis aims to examine Gal-3’s ability in assessing prognosis of HF patients. Method: We searched MEDLINE and Embase up to November 2014. Test performance characteristics were summarized using forest plots and hierarchical summary receiver operating characteristic curves. Results: The diagnostic odds ratio of Gal-3 in predicting mortality in chronic HF patients was 2.36 (95% CI: 1.71-3.26) and 2.30 (95% CI: 1.76-3.01) in acute HF patients. Conclusion: Elevated levels of Gal-3 are associated with mortality in both acute and chronic HF patients. However, current evidence does not support sole use of Gal-3 for prognosis evaluation of HF patients.